Endogenous endophthalmitis by Propionibacterium acnes associated with leflunomide and adalimumab therapy

被引:22
作者
Montero, J. A.
Ruiz-Moreno, J. M.
Rodriguez, A. E.
Ferrer, C.
Sanchis, E.
Alio, J. L.
机构
[1] Inst Oftalmol Alilcante, VISSUM, Retina Unit, Alicante, Spain
[2] Miguel Hernandez Univ, Dept Ophthalmol, Alicante, Spain
[3] Hosp Pio Rio Hortega, Allergy & Clin Immunol Unit, Valladolid, Spain
关键词
anti-TNF-alpha; endogenous endophthalmitis; Propionibacterium acnes;
D O I
10.1177/112067210601600225
中图分类号
R77 [眼科学];
学科分类号
100212 [眼科学];
摘要
PURPOSE. To report a case of unusual endogenous endophthalmitis associated with the use of leflunomide and adalimumab. METHODS. A 48-year-old woman on treatment with leflunomide and adalimumab for rheumatoid arthritis developed an endogenous endophthalmitis caused by Propionibacterium acnes. Diagnosis was confirmed by polymerase chain reaction and positive cultures. The patient underwent surgical treatment and intravitreal vancomycin, but the eye developed retinal fibrosis and untreatable retinal detachment. RESULTS. This report of endogenous endophthalmitis associated with the use of anti-tumor necrosis factor alpha (anti-TNF-alpha) drugs is consistent with those in the literature. P. acnes may induce pathologic reactions in compromised patients and cause endophthalmitis, but only after ocular surgery or in intravenous drug users. The Naranjo probability scale indicated a probable relationship between the drugs and the infection. CONCLUSIONS. Awareness of atypical infectious conditions in patients on anti-TNF-alpha drugs is critical for early diagnosis and good outcome.
引用
收藏
页码:343 / 345
页数:3
相关论文
共 4 条
[1]
BORISH L, 2003, MIDDLETONS ALLERGY P, P137
[2]
ENDOGENOUS ENDOPHTHALMITIS CAUSED BY PROPIONIBACTERIUM-ACNES [J].
DELAFUENTE, J ;
FERNANDEZCATALINA, P ;
SOPENA, B ;
CADARSO, L .
ARCHIVES OF OPHTHALMOLOGY, 1993, 111 (11) :1468-1468
[3]
Giles Jon T, 2004, J Intensive Care Med, V19, P320, DOI 10.1177/0885066604267854
[4]
Current and future pharmaceutical therapy for rheumatoid arthritis [J].
Ruderman, EM .
CURRENT PHARMACEUTICAL DESIGN, 2005, 11 (05) :671-684